Core Viewpoint - A class action lawsuit has been filed against Luminar Technologies, Inc. for alleged securities fraud, claiming that the company failed to disclose material adverse facts regarding its operations and compliance, particularly concerning CEO Austin Russell's undisclosed conduct [1][5]. Company Overview - Luminar Technologies specializes in advanced LiDAR hardware and software solutions for vehicles [4]. - The company issued its quarterly business update and financial results for Q4 2024 and the full year 2024 on March 20, 2025, and reiterated its guidance for the full year 2025 in its Q1 2025 update on May 14, 2025 [4]. Legal Proceedings - The class action lawsuit, Yskollari v. Luminar Technologies, Inc., was initiated in the United States District Court for the Middle District of Florida [1]. - Investors who purchased Luminar securities between March 20, 2025, and May 14, 2025, are eligible to participate in the lawsuit [1][7]. Allegations - The complaint alleges that Luminar's executives made false or misleading statements and failed to disclose significant risks related to CEO Austin Russell's conduct, which could jeopardize his position and the company's business [5]. - The lawsuit claims that the lack of transparency regarding Russell's situation undermined the company's financial guidance and misled investors [5]. Market Reaction - Following the announcement of Russell's resignation on May 14, 2025, Luminar's stock price dropped by $0.80, or 16.80%, closing at $3.96 per share on May 15, 2025 [6].

LOS ANGELES, July 24, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming September 12, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN) securities between March 24, 2023 and May 14, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR BIOHAVEN INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOV ...

NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into BellRing Brands, Inc. (NYSE: BRBR) for potential violations of the federal securities laws. If you invested in BellRing, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/bellring-brands-inc-class-action-lawsuit. Why is BellRing being Investigated? BellRing operates in the convenient nutrition category. The Company’s pr ...

PHILADELPHIA, July 23, 2025 /PRNewswire/ -- Berger Montague, with offices in Canada and throughout the United States, is currently investigating potential violations of the federal securities laws on behalf of shareholders of Ascot Resources Ltd. ("Ascot" or the "Company") (AOT.TO; AOTVF; BHQ.F; BHQ.DU; BHQ.MU).CLICK HERE TO LEARN MORE ABOUT THE INVESTIGATIONAscot, headquartered in Vancouver, BC, engages in the exploration and development of mineral properties in the United States and Canada. Its main asset ...

Investors can contact the law firm at no cost to learn more about recovering their losses​ LOS ANGELES, July 23, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises RxSight, Inc. (“RxSight” or “the Company”) (NASDAQ: RXST) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. RxSight investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Investors are encouraged to contact attorney Les ...

Core Viewpoint - Barnes & Noble Education, Inc. is under investigation for potential securities fraud and unlawful business practices, which has led to a significant drop in its stock price following the announcement of a delay in its annual report due to accounting issues [1][3][4]. Group 1: Investigation Details - Pomerantz LLP is investigating claims on behalf of investors regarding potential securities fraud by Barnes & Noble and its officers or directors [1]. - The investigation is focused on how the costs of digital sales were recorded, with early findings suggesting that accounts receivable may have been overstated by up to $23 million [3]. Group 2: Financial Impact - Following the announcement of the investigation and the delay in the annual report, Barnes & Noble's stock price fell by $2.36 per share, representing a 21.02% decrease, closing at $8.87 per share on July 21, 2025 [4]. Group 3: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [5].

Core Viewpoint - Neogen Corporation is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives misled investors regarding the integration with 3M and the financial health of the company during the class period from January 5, 2023, to June 3, 2025 [1][3]. Company Overview - Neogen Corporation engages in the development, manufacture, and marketing of products and services focused on food and animal safety [2]. - The company announced a merger with the Food Safety Division of 3M in December 2021, which was completed in September 2022 [2]. Allegations of the Lawsuit - The lawsuit alleges that Neogen's executives misrepresented the progress of the integration with 3M and downplayed inefficiencies that arose during this process [3]. - On January 10, 2025, Neogen reported a significant GAAP net income loss due to a $461 million non-cash goodwill impairment charge related to the 3M acquisition, alongside a reduction in revenue and EBITDA guidance for fiscal year 2025 [4]. - Following the announcement of its third quarter results on April 9, 2025, Neogen reported a loss of $11 million, a revenue decline of 3.4% to $221 million, and a significant drop in stock price by 28% [5]. - On June 4, 2025, Neogen projected a drop in EBITDA margin to the high teens from 22%, leading to a further stock price decline of over 17% [6]. Legal Process - Investors who purchased Neogen common stock during the class period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [7]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [8][9].

Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its product ALTO-100 and its business prospects [1][5]. Group 1: Lawsuit Details - The lawsuit is on behalf of purchasers of Alto common stock during the IPO on February 2, 2024, and securities purchased between February 2, 2024, and October 22, 2024 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the Court by September 19, 2025, to represent other class members [3]. Group 2: Allegations Against Alto Neuroscience - Defendants allegedly made materially false and misleading statements about Alto's business and operations [5]. - Specific claims include that ALTO-100 was less effective in treating major depressive disorder than represented, leading to overstated clinical and commercial prospects [5]. - The lawsuit asserts that when the true information became public, investors suffered damages [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has been consistently ranked among the top for securities class action settlements and has recovered hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

LOS ANGELES, July 22, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Neogen Corporation ("Neogen" or "the Company") (NASDAQ: NEOG) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between January 5, 2023 and June 3, 2025, inclusive (the "Class Period"), are ...

Core Viewpoint - A lawsuit has been filed against Fortrea Holdings Inc. and its senior executives for potential violations of federal securities laws, specifically related to the company's financial disclosures and performance claims [1][2]. Group 1: Company Background - Fortrea Holdings Inc. is a global contract research organization that provides biopharmaceutical product and medical device development solutions. It was spun off from Labcorp Holdings Inc. in June 2023 [3]. Group 2: Allegations and Financial Performance - The lawsuit alleges that Fortrea overstated the cost savings and margin improvements expected from exiting transition services agreements (TSAs) with Labcorp, as well as the revenue from pre-spin projects [4]. - Following a report from Jefferies on September 25, 2024, which indicated that the anticipated cost savings were not as significant as previously claimed, Fortrea's stock price fell by $2.73, or over 12%, from $22.21 to $19.48 per share [5]. - On March 3, 2025, Fortrea announced disappointing Q4 and full-year 2024 results, revealing lower-than-expected revenue and profitability from pre-spin projects, leading to a further decline in stock price by $3.47, or over 25%, from $13.85 to $10.38 per share [6].